SIZE XSSIZE SMSIZE MDSIZE LG

BCOP Oncology Pharmacy Updates Course

The Oncology Pharmacy Updates Course is a program designed for the practicing advanced level BCOP pharmacist. Covering new and ongoing therapeutic developments that have emerged within the last three years, the Updates course will provide you with up-to-date information, including recently published or ongoing studies from the past 2–3 years that you can immediately apply to your practice. 

Highlights

  • Learn about promising research and new treatment regiments.
  • Get clinical updates on treatment of tumor types and new supportive care therapies.
  • Find an overview of common clinical and technical issues in the hematology/oncology clinical setting.

BC1 – Updates on Immunotherapy in Bladder Cancer

BC2 – Updates in the Management of Veno-Occlusive Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS)
           New Options for the Management of Invasive Fungal Infections

BC3 – Updates on ALK Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

BC4 - Treatment of Non-Small Cell Lung Cancer (NSCLC) with a Focus on Immune Oncology

BC5 - The Changing Landscape of CDK 4/6 Inhibitors in Metastatic Breast Cancer

BC6 - Updates in Colorectal Cancer

BC7 - Immune Oncology updates in Non-Hodgkin Lymphoma (NHL)

BC8 - Integration of biomarker-driven and targeted therapy into the management of head and neck cancer (HNSCC)
           Updates to PARP inhibitors in ovarian cancer
           Drug Development – a focus on 340b updates

Each session will involve a recording of the speaker presenting their topic, a pre-test and post-test, but you will also have the opportunity to submit questions to the faculty and during their designated “office hours” you will have the opportunity to hear the answers to these questions and ask more. Don’t worry if you are unable to attend these “office hours” you will be able to listen to these sessions as well. You may choose to complete all sessions or select ones individually and still receive BCOP credit for modules which achieve passing scores.

HOPA Member Price: $225
Non-Member Price: $325

Purchase Now

Can also be purchased as part of the 2018 BCOP Program Bundle.

Activity type:

Application.

Accreditation Statement:

 logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. BCOP test must be completed by December 28, 2018.

education speaker bpslogo The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Test must be completed by December 28, 2018.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.


Sessions

BC1 - Updates on Immunotherapy in Bladder Cancer  

Description: This session is intended to take a closer look at the five immunotherapy agents added to the armament of treatment for bladder cancer within an approximate span of one year. Landmark clinical trials will be evaluated and this will lend to discussion of the niche for each drug, pharmaceutical pearls, and both overlapping and distinguishing features and toxicities. Immune-mediated adverse events management and current available data on markers of response will also be discussed. 

Learning Objectives
  • Examine the role of immunotherapy and associated markers in the treatment of urothelial carcinoma
  • Describe the results of clinical trials highlighting efficacy and safety of immunotherapy agents in urothelial carcinoma
  • Define the place in therapy for each immunotherapy agent
  • Identify immune-mediated adverse events and their management strategies 

 KParikh

Kinjal Parikh, PharmD BCOP
Kinjal Parikh graduated from the University of North Carolina at Chapel Hill in 2011 with her Doctorate of Pharmacy degree. She completed a post-graduate Pharmacy Practice Residency at the University of Utah and then continued on to a Hematology and Oncology Pharmacy Residency at the Huntsman Cancer Institute. Kinjal is now a clinical pharmacy specialist at the University of Texas M.D. Anderson Cancer Center in Genitourinary Medical Oncology. Her interests within pharmacy also include precepting, mentorship, and leadership.

Disclosure: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hour (.15 CEUs) under the ACPE universal activity number 0465-0000-18-042-H04-P.


BC2a: Updates in the Management of Veno-Occlusive Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS)

Description: Veno occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication following hematopoietic cell transplantation (HCT). Importantly, there is significant variability with respect to VOD/SOS diagnostic strategies, risk stratification, prophylaxis and treatment approaches. This program will focus on updates pertaining to VOD/SOS following HCT in order to improve clinician’s ability to design an evidence-based individualized pharmacotherapeutic care plan for the prevention and treatment of patients with VOD/SOS.

Learning Objectives

  • Assess the current evidence related to risk factors for developing VOD/SOS
  • Evaluate the efficacy and safety data regarding the prevention of VOD/SOS
  • Design an evidence-based individualized pharmacotherapeutic care plan for the treatment of patients with VOD/SOS

AGanetsky

Alex Gantesky, PharmD BCOP
Alex Ganetsky is a board-certified hematology/oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania. He specializes in malignant hematology and hematopoietic cell transplantation. He earned his Doctor of Pharmacy degree from Temple University in 2008 and subsequently completed a Pharmacy Practice Residency at University of North Carolina and a Hematology/Oncology Specialty Residency at Memorial Sloan-Kettering Cancer Center. Dr. Ganetsky has presented his work at national and international conferences and has published numerous articles in leading peer-reviewed journals. Dr. Ganetsky’s primary research focus is related to identifying novel methods to mitigate complications of hematopoietic cell transplantation.

Disclosure: Jazz – Advisory Board Member and Consultant - Honoraria

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.75 contact hour (.75 CEUs) under the ACPE universal activity number 0465-0000-18-043-H04-P.

BC2b: New Options for the Management of Invasive Fungal Infections

Description: Invasive Fungal Infections (IFIs) are frequent in hematologic cancer patient with a high rate of mortality, particularly in aspergillosis, ranging from 20% to 50%. Currently available antifungal agents for the treatment of IFIs include polyenes, echinocandins, and azoles. Over the last years, new options for the treatment of IFIs are available (intravenous posaconazole and isavuconazonium). This presentation will review the antifungal agents and their place in the prophylaxis and treatment of IFIs based on current Clinical Practice Guideline.

Learning Objectives

  • Describe the differences between the antifungal agents in the class of polyenes, echinocandins and azoles.
  • Define the place of each antifungal agents in the prophylaxis and treatment of IFIs for cancer
  • Select the best antifungal therapy based on patient characteristic, interaction and adverse event profile.

Jean-Phillip Adam

Jean-Phillip Adam, BPharm MSc BCOP BCPS
Jean-Philippe Adam holds a bachelor's degree in pharmacy (2009) and a master's degree in hospital pharmacy (2011) from Laval University at Quebec (Canada). He completed a 6-month hemato-oncology fellowship at the Ottawa General Hospital and the Quebec University Hospital Center. He has been Board Certified Pharmacotherapy Specialists (BCPS) and Board Certified in Oncology Pharmacy (BCOP) since 2013 and 2016 respectively. Mr. Adam work as a clinical oncology pharmacist at outpatient and inpatient unit the Centre Hospitalier de l’Université de Montréal since 2011. He has more than fifteen publications and sixty presentations to his credit.

Disclosures: Abbive – Consultant and Speaker – Honoraria, Janssen – Consultant – Honoraria, Lundbeck – Consultant – Honoraria, Novartis – Speaker – Honoraria, Apobiologix – Speaker – Honoraria, Familiprix – Speaker – Honoraria, APPSQ – Speaker - Honoraria

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.75 contact hour (.75 CEUs) under the ACPE universal activity number 0465-0000-18-044-H04-P.


BC3: Updates on ALK Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Description: It has been approximately 10 years since the initial discovery of ALK gene rearrangements in NSCLC and several TKIs has been introduced to target this mutation. The presentation will focus on approved ALK inhibitors (especially those that have been recently approved in the last 3 years i.e alectinib and brigatinib), ALK inhibitors in development, and the comparison of adverse effects and effectiveness data between them. We will discuss emerging controversies about the choice of first-line and second-choice ALK inhibitors and the role of TKIs in the treatment of brain metastasis. Audience: pharmacists involved in oncology treatments.

Learning Objectives

  • Examine the use of different ALK inhibitors for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Distinguish efficacy and toxicities of newly approved ALK inhibitors in the treatment of NSCLC
  • Choose appropriate ALK inhibitor based on patient specific factors and indication for the treatment of NSCLC.

mwong

Milena Wong, PharmD BCOP
Dr. Wong is a clinical pharmacy specialist in the Division of Pharmacy at the University of Texas MD Anderson Cancer Center in Houston. Her responsibilities include collaborating with the medical oncology multidisciplinary team focused on patients with thoracic and head and neck cancers. She received both her Bachelor of Science and Doctor of Pharmacy degrees from the University of Florida. She completed her pharmacy practice residency at Mount Sinai St. Luke’s, New York, NY, and PGY-2 hematology/oncology pharmacy residency at Smilow Cancer Hospital at Yale-New Haven in New Haven, CT.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.10 CEUs) under the ACPE universal activity number 0465-0000-18-045-H04-P.


BC4: Treatment of Non-Small Cell Lung Cancer (NSCLC) with a Focus on Immune Oncology

Description: This session reviews the new treatment options for non-small cell lung cancer. Newer immunotherapy and targeted agents will be reviewed for place in therapy, adverse effects and safety and efficacy. The presentation will also review trials that approved the indications for the drugs.

Learning Objectives

  • Examine the use of immunotherapy in non-small cell lung cancer (NSCLC)
  • Compare and contrast targeted therapy in NSCLC
  • Distinguish efficacy and toxicities of newly approved therapies in the treatment of NSCLC

Sonia Thomas

Sonia Thomas, PharmD BCOP
Dr. Sonia Amin Thomas has been an assistant professor of pharmacy practice at Philadelphia College of Osteopathic Medicine School of Pharmacy in Suwanee, GA for 5 years. She has a practice site at Wellstar North Fulton Hospital and Northwest Georgia Oncology Centers in Roswell, GA where she rounds inpatient with the oncologist and sees patients in the clinic and infusion centers to counsel on intravenous chemotherapy and assists the oncologist with a focus on supportive care and oral chemotherapy counseling. She also works PRN at North Fulton as a clinical pharmacist. She completed her PGY1 residency in Columbus, GA and PGY2 in oncology in Detroit, MI and became board certified as an oncology pharmacist a year ago. Sonia has various publications in the oncology field and is always looking for more opportunities for research.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (1.0 CEUs) under the ACPE universal activity number 0465-0000-18-046-H04-P.


BC5: The Changing Landscape of CDK 4/6 Inhibitors in Metastatic Breast Cancer

Description: CDK 4/6 inhibitors have been practice changing for hormone receptor-positive metastatic breast cancer.  This session will review these medications, analyze key studies, address their applicability, and discuss side effects, their management, and the pharmacist’s role.

Learning Objectives

  • Examine the use of palbociclib, ribociclib, and abemaciclib in hormone receptor-positive metastatic breast cancer.
  • Distinguish efficacy of newly approved therapies in the treatment of hormone receptor-positive metastatic breast cancer.
  • Compare adverse effect profiles for newly approved therapies utilized in hormone receptor-positive metastatic breast cancer.
  • Assess the data on important questions in hormone receptor-positive metastatic breast cancer: sequencing and choice of therapy, changes in front-line and second-line therapies.

Bonnie Boster

Bonnie Boster, PharmD BCOP
Bonnie Lin Boster earned her BS in Pharmacy and PharmD degrees from The Ohio State University. She completed her Oncology Pharmacy Residency at South Texas Veterans Health Care System, UT Health Science Center in San Antonio, Texas.  Bonnie works at the University of Texas M.D. Anderson Cancer Center as a clinical pharmacy specialist in Breast Medical Oncology.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-047-H04-P.


BC6: Updates in Colorectal Cancer

Description: Though TNM stage remains the most important determinant of patient prognosis additional factors such as microsatellite instability (MSI) and the location of the tumor impact prognosis as well as treatment options for patients.  This session will review the impact MSI has on prognosis and treatment of patients with colon cancer.  Additional discussions will discuss the impact the location of the tumor has on survival and treatment.

Learning Objectives

  • Describe the impact that tumor instability has in the development and prognosis of colon cancer.
  • Explain the role biomarkers such as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR), have on treatment decisions for patients with various stages of colon cancer.
  • Review the anatomical and pathologic factors of colon cancers located in the “right” and “left” side of the colon.
  • Outline how primary tumor location (PTL) impacts both prognosis and, potentially, treatment options for patients.

Patrick Medina

Patrick Medina, PharmD BCOP
Dr. Medina is a Professor at the University of Oklahoma College of Medicine and a Director of Pharmacy at the Stephenson Cancer Center.  Dr. Medina obtained both a B.S. in pharmacy and a Pharm.D. Degree from Rutgers University in New Jersey.  He completed a pharmacy practice residency at the University of Illinois, then an Oncology Pharmacy Fellowship at the Cancer Institute of New Jersey. 

In addition, he has taught in the ASHP/ACCP Oncology Review Course and has done numerous invited CE presentations, book chapters, and review articles published in peer review journals, and is Co-Editor in Chief of the Oncology Pharmacist and Journal of Hematology Oncology Pharmacy.

Disclosures: TBA

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-048-H04-P.


BC7: Immune Oncology updates in Non-Hodgkin Lymphoma (NHL)

Description: This webinar will discuss the up and coming use of immunotherapy in the management of NonHodgkin’s Lymphoma (NHL).  Chimeric antigen receptor (CAR) T cell therapy will be discussed in depth including the recent FDA approval of axicabtagene ciloleucel as well as management of toxicities associated with CAR T cell therapy.  Data investigating the use of checkpoint inhibitors in NHL will also be presented.  The role of the pharmacist in managing NHL patients being treated with immunotherapy will be highlighted. 

Learning Objectives

  • Examine the role of CAR-T cell therapy in treating patients with NonHodgkin’s Lymphoma (NHL).
  • Analyze recent data utilizing checkpoint inhibitors in NHL. 
  • Identify patients with NHL who are appropriate candidates for treatment with immunotherapy.
  • Illustrate the role of the pharmacist in the management of patients receiving treatment with immunotherapy.

 

Helen Marshall

Helen Marshall, PharmD BCOP BCPS
Helen M. Marshall, PharmD BCOP BCPS is a Clinical Pharmacist at the Seattle Cancer Care Alliance and University of Washington Medical Center. She is also a Clinical Assistant Professor in the University of Washington School of Pharmacy. Dr. Marshall is a clinical specialist in the Bezos Family lmmunotherapy.  Clinic and in the Hematopoietic Stem Cell Transplant Clinic. She was previously a specialist in thoracic, head and neck oncology. She also previously cared for patients in the SCCA pain management and anticoagulation clinics via collaborative practice.

Dr. Marshall earned her Doctor of Pharmacy degree from the University of Washington School of Pharmacy in Seattle, Washington. She completed a postgraduate year one pharmacy practice residency at the University of North Carolina Hospitals in Chapel Hill, North Carolina, and a postgraduate year two oncology specialty residency at Duke University Hospital in Durham, North Carolina. She is a board certified pharmacotherapy specialist and a board certified oncology pharmacist.

Dr. Marshall is an active member of Hematology/Oncology Pharmacy Association (HOPA), the American Society of Health Systems Pharmacists (ASHP), the American College of Clinical Pharmacy (ACCP), and Washington State Pharmacy association (WSPA).

Disclosures: No financial relationships exist with commercial interests. 

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-049-H04-P.


BC8a: Integration of biomarker-driven and targeted therapy into the management of head and neck cancer (HNSCC)

Description: The landscape of the management of head and neck cancers (HNSCC) has progressively changed over the course of the previous few years.  The use of HPV p16 testing in oropharyngeal SCC as a predictive biomarker has prompted research in this disease state to determine additional biomarkers that may better guide therapeutic options.  While combination cisplatin and radiation therapy remain the standard of care for advanced HNSCC, early discussions of biomarker driven therapy have prompted the consideration of less toxic regimens for better risk subtypes. In addition, the inclusion of targeted and immunotherapies has allowed for improved outcomes and additional therapy options for patients with recurrent and metastatic disease, and may play a role in the peri-operative setting as well.  This session would provide an update to the audience in the management of head and neck cancers and novel approaches in the pipeline.

Learning Objectives

  • Review the epidemiology and pathogenesis of head and neck cancers (HNSCC).
  • Describe the relevant biomarkers associated with HNSCC and how they may be incorporated into management decisions.
  • Explain the expanded roles of immunotherapy, including PD-1 and PD-L1 inhibitors in the treatment of patients with HNSCC.

Angela Michael

Angela Michael, PharmD BCOP
Angela Michael, PharmD, BCOP practices in both acute care and ambulatory oncology at Henry Ford Hospital in Detroit, Michigan and serves as the PGY2 oncology residency director. Her most recent position within the institution is as the new clinical pharmacy specialist establishing the high-risk monitoring program (HRMP) within the Henry Ford Cancer Institute.  Angela graduated from Wayne State University, completed her PGY-1 residency at the University of Illinois at Chicago and PGY-2 specialty residency in oncology at Memorial Sloan Kettering Cancer Center. 

Disclosures: No financial relationships exist with commercial interests. 

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.75 contact hour (.75 CEUs) under the ACPE universal activity number 0465-0000-18-050-H04-P.

BC8b: Updates to PARP Inhibitors in Ovarian Cancer

Description: This presentation will briefly review the basic mechanisms of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors and their role in hormone driven cancers, and the basic pharmacology of available PARP inhibitors. This presentation will consist of a review of pertinent literature supporting the use of PARP inhibitors in gynecologic malignancies and their place in therapy based on available data. Lastly, the presentation will address future directions for PARP inhibitors in gynecologic and non-gynecologic malignancies.

Learning Objectives

  • Compare basic pharmacology of available PARP inhibitors.
  • Develop recommendations for the use of PARP inhibitors for the treatment of gynecologic malignancies.
  • Apply recent advances in the use of PARP inhibitors for targeted therapy of gynecologic malignancies.

Allison Guyton

Allison Guyton, PharmD BCOP BCPS
Allison Guyton PharmD, BCOP, BCPS is a board-certified clinical pharmacist at UAB Hospital in Birmingham, Alabama. Allison currently works as a clinical pharmacist in the Hematology/Oncology ambulatory clinic. She serves as a therapeutic resource for physicians and provides clinical oversight, education, and follow-up to patients on oral chemotherapy. She is an active preceptor for students and residents. Allison graduated from Auburn University in 2013. She completed her PGY1 in 2014 and PGY2 in Oncology in 2015 at UAB Hospital and has continued to practice there since that time.

Disclosures: No financial relationships exist with commercial interests. 

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.75 contact hour (.75 CEUs) under the ACPE universal activity number 0465-0000-18-051-H04-P.

BC8c: Drug Development – a focus on 340b updates

Description: Since its inception, the 340B drug discount program has been a center of controversy.  Strong opinions exist regarding this program and the intended use of the cost savings obtained by the entities enrolled.  This discussion will outline four of the current controversies, describe the issues, and explain the impact on oncology pharmacy practices

Learning Objectives

  • Explain the impact the Affordable Care Act (ACA) has had on the 340B drug discount program and the controversies that have ensued.
  • Outline the requirements to be a covered patient in a 340B program.
  • Describe the orphan drug exclusion and the impact of the rule on oncology practices.
  • Explain the impact on oncology practices of the Centers for Medicare and Medicaid Services reimbursement change for disproportionate share hospitals.

Scott Soefje

Scott Soefji, PharmD, MBA BCOP FCCP
Scott Soefje, PharmD, MBA, BCOP, FCCP is the Director of Pharmacy Cancer Care Services at the Mayo Clinic in Rochester, MN.   He earned his BS in Pharmacy and a PharmD from The University of Texas at Austin and an MBA focusing on healthcare from The George Washington University. He completed an ASHP accredited Oncology Specialty Residency from the Audie L. Murphy Veterans Hospital in San Antonio and a Clinical Pharmacology Fellowship from the University of Texas M.D. Anderson Cancer Center in Houston. He has been Board Certified in Oncology Pharmacy since 2000.  He has a breath of professional experience from academia to clinical specialist to industry medical science liaison and finally pharmacy administration.

Disclosures: No financial relationships exist with commercial interests. 

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.5 contact hour (.5 CEUs) under the ACPE universal activity number 0465-0000-18-052-H04-P.

 

 

 

 

xs
sm
md
lg